Physitrack's Agentic EMR: Early Access, Late Revenue
Growth is the best of the year, but the margin reset funds a product that will not bill until 2027.
PTRK.ST · Earnings Call · 2026-10-20
A small-cap software story with a big new product
Physitrack reported Q3 2026 with revenue of €3.6 million, up 14% year on year and 11% at constant currency—the strongest growth of the year. Lifecare rose 15%, and the core home exercise prescription platform grew 26%. That is impressive for a product more than a decade old. But adjusted EBITDA fell 8% to €1.1 million, a 31% margin versus 38% a year ago. Management framed the decline as planned investment in North America and three product launches. The quarter is therefore not a simple beat or miss; it is a deliberate margin reset to fund a platform expansion.
The expansion is the EMR: an electronic medical record system with agentic AI at its core. It opened early access on September 28; by the call, almost 500 clinics and nearly 5,000 users had signed up. A beta of about 50 clinics is live, with wider release on November 2. Management also launched remote therapeutic monitoring and Educational Modules. Those are three new revenue streams, but only one—RTM—is open for trials; EMR paid subscriptions begin January 2027, and Educational Modules begin commercializing in Q4.
We built an EMR with agentic AI at the core. That's the important distinction here. AI isn't an add-on. It's not a little feature sitting somewhere on the side. It's right at the heart of the system.
This is the central claim. It is also the central risk. The early access list is not revenue. Henrik Molin gave a rough bridge: about 60% of sign-ups are existing customers, 7% former customers, 34% new. Apply a 35% conversion to existing and 20% to new, and the current sign-ups are worth about €1 million of ARR. Then he added the caveat that matters: “Just for the sign-ups that we've seen so far in the few weeks, it's worth about EUR 1 million ARR, give or take. It's all theoretical.” — Henrik Molin, CEO and Co-Founder · 2026-10-20 Investors should treat that as a scenario, not guidance. The conversion rate is now the KPI to watch.
What changed in the P&L
The cleanest detail is that this was the first quarter with no adjusting items. Matt Poulter said: “This is actually the first quarter that we have no adjusting items.” — Matt Poulter, CFO · 2026-10-20 After years of restructuring, acquisitions, and legal costs running through adjustments, reported EBITDA and adjusted EBITDA now converge. That is a genuine quality improvement. It also means the margin compression is not an accounting artifact; it is real spending.
Operating costs were about €2.5 million in Q3. “The operating costs in Q3 were around EUR 2.5 million. We do expect them to ease slightly in Q4.” — Matt Poulter, CFO · 2026-10-20 Management expects them to stay roughly around that level through the first half of 2027, with CapEx also flat at roughly €0.8 million. The cost base is largely fixed, and revenue from EMR, RTM, and Educational Modules should carry very high gross margins. The EBITDA margin target of 40%-45% is unchanged. Henrik said: “I don't see why we wouldn't come back to where we're supposed to be, which is 40%-45%.” — Henrik Molin, CEO and Co-Founder · 2026-10-20 But he also declined to give specific Q4 or 2027 margin guidance. The medium-term target is intact; the near-term path is not yet quantified.
The other side of the quarter is Wellness. Revenue grew only 2%, but adjusted EBITDA margin jumped to 38% from 17%, and revenue retention improved to 96.6%. That is a successful cleanup. The blemish is a large customer loss, which pulled Wellness ARR down to €0.7 million and left group ARR at €13.6 million, up 6% year on year but flat on Q2. Lifecare kept compounding; Wellness is smaller and more profitable but no longer growing fast enough to offset a single account loss. This is the contrast inside the report: a growth engine funding a new platform, and a reset segment that is still fragile.
Riding the agentic wave—but in a vertical
Agentic AI is no longer a niche phrase in this earnings season. Other reporters are discussing agentic AI in telecom, software, insurance, and commerce. Physitrack is not an infrastructure play or a horizontal AI platform. Its version is vertical: an EMR for physical therapy and adjacent clinics, where the AI can schedule, document, bill, and prescribe home exercise in one workflow. The company argues that owning the clinical workflow makes the revenue sticky and turns the software from an expense into a revenue-generating tool for clinics. That is a credible wedge because Physitrack already has distribution into a large base of clinicians.
The early numbers support product-market interest, not yet product-market revenue. The EMR beta has been live for only weeks. The wide release is November 2. Paid subscriptions start January 2027. The academic U.S. health system is still in contracting, with about $130,000 in annual revenue expected and $390,000 over three years, but it will not go live until early 2027. The Metropolitan Safety Net system goes live in Q4 at about $26,500 in year-one license revenue, with RTM potentially adding roughly $80,000 if 86 practitioners enroll 10 patients each. Those are small numbers against a €13.6 million ARR base, but they are proof points for a much larger enterprise motion.
Cash, buyback, and the burden of proof
Physitrack generated positive operating cash flow for the eighth consecutive quarter; free cash flow was €0.2 million. Net debt fell to €3.7 million, with €1.9 million of liquidity and covenant headroom. The positive cash flow record is important because it funds the investment without an equity raise. The buyback is tiny—about €120,000 this year and €250,000 a year from 2027—but it is structured to fund management incentives without dilution, using treasury shares. That is sensible capital management for a company of this size.
The burden of proof now shifts to conversion. The quarter shows real revenue growth, a clean adjusted EBITDA base, and a product launch that has attracted meaningful early interest. It also shows a lower margin, a lost Wellness customer, and a new revenue stream that will not bill until next year. If the EMR conversion is even close to management's theoretical math, operating leverage could be dramatic because the cost base is largely fixed. If conversion is slower, the margin target stays a medium-term aspiration and the stock has to wait. The report is not routine; it is a small-cap software company betting its next leg of growth on an agentic clinical platform. The next two quarters will tell us whether early access becomes recurring revenue.